{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for atomoxetine in Related Substance Name (approximate match)
Status:
Possibly Marketed Outside US
Source:
Mandelamine by Winkler, F.W.
Source URL:
First approved in 2002
Source:
M006
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Mandelic acid is an aromatic alpha hydroxy acid that is used for the treatment of urinary tract infections. The drug is marketed in Canada under the name Mandelamine (as a complex with methenamine). Mandelic acid exerts its antibacterial effect mainly by increasing urine acidity. Moreover, mandelic acid is used as a serum for the treatment of wrinkles.
Status:
Possibly Marketed Outside US
Source:
Mandelamine by Walker, J.
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
(S)-Mandelic acid (L-Mandelic acid) is an enantiomer of the aromatic alpha hydroxy acid that is used in the production of pharmaceuticals for its antibacterial activity and administered as an oral antibiotic or a treatment for urinary tract infections. Well-known ester drugs, such as cyclandelate and homatropine, are derived from L-mandelic acid. Because of its antibacterial properties, L-mandelic acid is an alternative to α-hydroxy acids in skin care products. Among the most popular ingredients in both skin care and anti-aging products, L-mandelic acid now represents a multi-billion dollar industry.
Status:
US Approved Rx
(2013)
First approved in 1958
Class:
MIXTURE
Status:
Investigational
Source:
NCT03534063: Not Applicable Interventional Completed Pain, Postoperative
(2018)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00915733: Phase 4 Interventional Completed Myocardial Infarction
(2009)
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
Source:
ANDA079017
(2010)
Source URL:
First approved in 2002
Source:
NDA021411
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Atomoxetine is indicated for the treatment of Attention-Deficit/Hyperactivity Disorder. The precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter. Most common adverse reactions are: nausea, vomiting, fatigue, decreased appetite, abdominal pain, and somnolence, constipation, dry mouth, dizziness, erectile dysfunction, and urinary hesitation. Atomoxetine is a substrate for CYP2D6 and hence concurrent treatment with CYP2D6 inhibitors such as bupropion (Wellbutrin) or fluoxetine (Prozac) is not recommended, as this can lead to significant elevations of plasma atomoxetine levels.
